权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MMP-14 Chimeric Ligands for Targeted Imaging of Metastatic Tumors

用于转移性肿瘤靶向成像的 MMP-14 嵌合配体

基本信息

批准号：
9035372
负责人：
Clifford Berkman
金额：
$ 19.63万
依托单位：
WASHINGTON STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9035372
关键词：
Achievement Active Sites Affinity Aftercare Attention Binding Binding Sites Biological Markers Breast Breast Cancer Cell Breast Cancer Patient Catalytic Domain Cause of Death Cell membrane Cells Characteristics Clinical Collagen Confocal Microscopy Detection Development Diagnosis Diagnostic Disease Disseminated Malignant Neoplasm Dyes Early Diagnosis Elements Ensure Exocytosis Extracellular Matrix Family Fluorescent Dyes Foundations Goals Health Hemopexin Homodimerization Hydrolysis Image In Vitro Individual Inhibition of Matrix Metalloproteinases Pathway Integral Membrane Protein Label Length Ligands MMP14 gene Malignant Neoplasms Matrix Metalloproteinases Membrane Neoplasm Circulating Cells Neoplasm Metastasis Normal tissue morphology Optics Outcome Patient-Focused Outcomes Patients Peptides Play Positron-Emission Tomography Primary Neoplasm Process Proliferating Quality of life Radiolabeled Research Screening for cancer Solvents Specificity Staging Technology Testing Therapeutic Therapeutic Agents Translating Work angiogenesis base cancer cell clinically relevant expectation imaging agent imaging modality imaging platform imaging probe in vivo in vivo imaging inhibitor/antagonist innovation malignant breast neoplasm microscopic imaging migration molecular imaging novel optical imaging outcome forecast overexpression radiotracer scaffold small molecule statistics targeted agent targeted imaging targeted treatment tumor tumor growth tumor progression tumorigenic

项目摘要

DESCRIPTION (provided by applicant): The proposed work is aimed at developing a selective MMP-14 probe for detecting metastatic and pro-tumorigenic cancer cells characterized by the over-expression of MMP-14. This will be achieved by optimizing a chimeric heterobivalent platform targeted simultaneously to two separate domains of MMP-14. Ligands to both the active site of the catalytic domain and the hemopexin domain will be tethered through a modular linker unit that can be varied in length to match the distance between the two domains. In a solvent exposed region of the linker, a near-IR dye will be installed to allow the heterobivalent platform to selectively label MMP-14- positive cells for detection by confocal microscopy and in vivo optical imaging. This achievement is important because it will ensure the feasibility of advancing this technology to PET imaging applications. In all likelihood, this general strategy can be applied to the selective targeting of other MMPs that serve as disease biomarkers. Our central hypothesis is that a high-affinity MMP-14-specific heterobivalent platform can be developed by optimizing the linker length between a MMP catalytic domain inhibitor and hemopexin domain ligand. When outfitted with a fluorescent dye, this chimeric platform will selectively label MMP-14-positive cells for in vitro and in vivo detection by confocal microscopy and optical imaging, respectively. The rationale for undertaking the proposed research is that the MMP-14-specific imaging platform will serve as the foundation for developing a clinically-relevant imaging modality for the diagnosis and post-treatment assessment of breast and other tumors characterized by over-expression of MMP-14. The approach is innovative in that it aims to selectively target the membrane-bound MMP-14 with a heterobivalent platform tailored to the distance between two of MMP-14's targetable domains rather than optimizing the affinity of scaffolds targeted to a single binding site. In Aim #1, we will test the working hypothesis that optimizing the linker length between a MMP catalytic domain inhibitor and hemopexin domain ligand will result in greater and selective affinity for MMP-14 than monovalent ligands or inhibitors. It is our expectation that the distance between the two domains will provide a unique and additional specificity element to the proposed chimeric heterobivalent platform, which can be tailored to individual MMPs, including MMP-14. Aim 2 is focused on proving-the-concept that enhanced binding to MMP-14 can be accomplished with heterobivalent platform and that fluorescently-labeling this platform with a near-IR fluorescent dye will enable optical in vivo imaging of MMP-14-positive tumors. At the conclusion of these studies, it is our expectation that a working probe for targeting MMP-14-positive tumors will be available for subsequent radiolabeling and the development of a clinically-relevant PET imaging agent for pro-metastatic tumors.